Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of romiplostim for chemotherapy-induced thrombocytopenia during FOLFOX-based chemotherapy in gastrointestinal or colorectal cancer
2017-002992-25Phase 3Active
- Sponsor
- Amgen
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Romiplostim + FOLFOX-based chemotherapy with Placebo + FOLFOX-based chemotherapy (2 arms). Primary endpoint: No thrombocytopenia-induced modification of myelosuppressive treatment in cycles 2 and 3. Started Jul 2019; status: active.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2017-002992-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002992-25.